Analysis of leukocyte adhesion molecule PSGL-1 activation caused by inhibition of vascular endothelial growth factor(VEGF)

老年性黄斑变性(AMD)是发达国家50岁以上人群视力障碍的主要原因。近年来，抗血管内皮生长因子抗体或其片段被用于AMD的临床治疗，越来越多的证据表明，抗血管内皮生长因子治疗可能会导致动脉血栓栓塞症相关的全身并发症。在目前的研究中，我们假设白细胞激活参与了抗血管内皮生长因子治疗引起的动脉血栓形成过程，并试图阐明其机制。因此，我们的数据表明，给予抗血管内皮生长因子抗体不会引起白细胞的激活；然而，这也为进一步评估抗血管内皮生长因子治疗导致动脉血栓栓塞症的机制、血小板激活的可能相关性提供了有益的信息。

Age-related macular degeneration(AMD) is a leading cause of visual disturbance among people over age 50 in the developed country. Recently, anti-VEGF antibody or its fragment is used as therapeutic agent for AMD in the clinical setting, and growing evidence have indicated that anti-VEGF therapy may cause the systemic complications related to arterial thromboembolism. In the current study, we hypothesized that leukocyte activation participates in the process of arterial thromboembolism formation caused by anti-VEGF therapy and sought to elucidate the mechanism. Consequently, our data demonstrates that administration of anti-VEGF antibody causes no leukocyte activation ; however, it also indicates the beneficial information to the further evaluation of the mechanism, possible relevance of platelet activation in arterial thromboembolism due to anti-VEGF therapy.